Skip to main content

Table 3 MACCE of In-Hospital and 12-Months Follow-Up

From: Efficacy and safety of standard and low dose ticagrelor versus clopidogrel in east AsianPatients with chronic total occlusion undergoing percutaneous coronary intervention: a single center retrospective study

VariablesTicagrelor 90 mg (n = 171)Ticagrelor 60 mg (n = 178)Clopidogrel 75 mg (n = 176)P-value
MACE in hospital
 All-cause mortality, n(%)1 (0.6%)1 (0.6%)2 (1.1%)0.848
 MI, n(%)2 (1.2%)1 (0.6%)2 (1.1%)0.749
 Stent thrombosis, n(%)1 (0.6%)2 (1.1%)4 (2.3%)0.465
 Stroke, n(%)1 (0.6%)1 (0.6%)1 (0.6%)1
 TVR, n(%)3 (1.8%)2 (1.1%)7 (4.0%)0.213
 Overall MACCE, n(%)5 (2.9%)5 (2.8%)9 (5.1%)0.454
MACE during 12-month follow-up
 All-cause mortality, n(%)2 (1.2%)1 (0.6%)2 (1.1%)0.749
 MI, n(%)2 (1.2%)3 (1.7%)5 (2.8%)0.576
 Stent thrombosis, n(%)4 (2.3%)4 (2.2%)6 (3.4%)0.792
 Stroke, n(%)1 (0.6%)01 (0.6%)0.551
 TVR, n(%)4 (2.3%)5 (2.8%)13 (7.4%)0.047
 Overall MACCE, n(%)11 (6.4%)13 (7.3%)25 (14.2%)0.023
  1. Abbreviations: MACCE Major adverse cardiac and cerebral events, TVR Target vessel revascularization, MI Myocardial infarction